Jun 2026 (Q2 FY26) — Aug 12, 2026
MaxCyte Q2 FY26 — Genentech Partnership and Return to Growth
Read the full callMaxCyte (MXCT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
MaxCyte earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 7.3 | −14.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -140.7 | +26.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -8.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.3 0.00% · $0
Performance −19.3% 1Y
1Y: $1.61 on 17 Oct 2025 → $1.3. High $1.76 (28 Nov 2025), low $0.68 (18 Feb 2026).
- Previous close
- $1.3
- 52-week range
- $0.68 – $1.76
- One year
- −25.71%
Overview
- Symbol
- MXCT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
MaxCyte earnings calls (MXCT)
Financials
What the filings say
Net profit, year on year: +28% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 9 | 10 | 9 | 7 | 7 | 10 | 7 |
| Operating profit | -14 | -13 | -12 | -14 | -14 | -11 | -6 | -10 |
| Operating margin | −172.1% | −148.4% | −118.3% | −167.2% | −207.2% | −153.8% | −64.1% | −140.7% |
| Profit before tax | -12 | -11 | -10 | -12 | -12 | -10 | -5 | -9 |
| Net profit | -12 | -11 | -10 | -12 | -12 | -10 | -5 | -9 |
| EPS ($ per share) | -0.11 | — | -0.10 | -0.12 | -0.12 | — | -0.04 | -0.08 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | — | -95 | -114 | -138 | -176 | -217 | -261 |
| Total liabilities | — | 19 | 21 | 33 | 36 | 33 | 31 |
| Fixed assets | — | 5 | 8 | 24 | 24 | 20 | 18 |
| Investments | — | 16 | 207 | 216 | 122 | 127 | 83 |
| Total assets | — | 52 | 284 | 287 | 268 | 239 | 203 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -9 | -9 | -11 | -15 | -22 | -28 | -34 |
| Cash from investing | 0 | -17 | -195 | -25 | 55 | 7 | 26 |
| Cash from financing | 12 | 29 | 235 | 3 | 2 | 2 | 1 |
| Net cash flow | 4 | 4 | 29 | -37 | 35 | -19 | -8 |
| Capital expenditure | -1 | -2 | -4 | -18 | -4 | -2 | -2 |
| Free cash flow | -10 | -11 | -15 | -33 | -25 | -29 | -36 |
Insider filings
11 filings between Mar 17, 2026 and Jun 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$8.3K
1 sale by 1 insider
Compensation
not trading decisions- 10
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Swirsky Douglas J | — | $8.3K | Mar 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | BALTHROP PATRICK J Director | Award | 30,421 | $0 |
| Jun 17, 2026 | Al-Wakeel Yasir B. Director | Award | 30,421 | $0 |
| Jun 17, 2026 | Brooke William W Director | Award | 30,421 | $0 |
| Jun 17, 2026 | Collins Cynthia Director | Award | 30,421 | $0 |
| Jun 17, 2026 | DOUGLAS RICHARD Director | Award | 30,421 | $0 |
| Jun 17, 2026 | Erck Stanley C Director | Award | 30,421 | $0 |
| Jun 17, 2026 | Hemrajani Rekha Director | Award | 30,421 | $0 |
| Jun 17, 2026 | Johnston John Joseph Director | Award | 30,421 | $0 |
| Apr 15, 2026 | Ahuja Parmeet Chief Financial Officer | Award | 187,500 | $0 |
| Mar 27, 2026 | Masoud Maher President and CEO | Award | 300,000 | $0 |
| Mar 17, 2026 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Sale | 10,142 | $8.3K |
| Aug 13, 2025 | Erck Stanley C Director | Purchase | 100,000 | $137.2K |
| Aug 13, 2025 | Brooke William W Director | Purchase | 50,000 | $64.5K |
| Aug 13, 2025 | DOUGLAS RICHARD Director | Purchase | 80,000 | $111.0K |
| Aug 13, 2025 | Masoud Maher President and CEO | Purchase | 75,000 | $102.9K |
| Aug 13, 2025 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Purchase | 50,000 | $64.5K |
| Jun 25, 2025 | Hemrajani Rekha Director | Sale 10b5-1 plan | 10,684 | $22.4K |
| Jun 18, 2025 | BALTHROP PATRICK J Director | Award | 29,210 | $0 |
| Jun 18, 2025 | Brooke William W Director | Award | 29,210 | $0 |
| Jun 18, 2025 | Collins Cynthia Director | Award | 29,210 | $0 |
| Jun 18, 2025 | DOUGLAS RICHARD Director | Award | 29,210 | $0 |
| Jun 18, 2025 | Erck Stanley C Director | Award | 29,210 | $0 |
| Jun 18, 2025 | Hemrajani Rekha Director | Award | 29,210 | $0 |
| Jun 18, 2025 | Al-Wakeel Yasir B. Director | Award | 29,210 | $0 |
| Jun 18, 2025 | Johnston John Joseph Director | Award | 29,210 | $0 |
| Mar 18, 2025 | Sandoval David I. GENERAL COUNSEL | Sale | 353 | $1.1K |
| Mar 18, 2025 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Sale | 6,939 | $22.1K |
| Mar 18, 2025 | Soleymannezhad Ali Chief Commercial Officer | Sale | 1,211 | $3.9K |
| Mar 14, 2025 | Sandoval David I. GENERAL COUNSEL | Award | 23,125 | $0 |
| Mar 14, 2025 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Award | 37,500 | $0 |
| Mar 14, 2025 | Soleymannezhad Ali Chief Commercial Officer | Award | 34,625 | $0 |
| Jan 27, 2025 | Johnston John Joseph Director | Sale 10b5-1 plan | 3,000 | $13.9K |
| Jan 27, 2025 | Johnston John Joseph Director | Option exercise 10b5-1 plan | 3,000 | $8.8K |
| Jan 13, 2025 | Sandoval David I. GENERAL COUNSEL | Sale | 4,466 | $20.3K |
| Dec 26, 2024 | Johnston John Joseph Director | Option exercise 10b5-1 plan | 3,000 | $8.8K |
| Dec 26, 2024 | Johnston John Joseph Director | Sale 10b5-1 plan | 3,000 | $12.0K |
| Dec 9, 2024 | Johnston John Joseph Director | Option exercise 10b5-1 plan | 1,121 | $1.8K |
| Dec 9, 2024 | Johnston John Joseph Director | Sale 10b5-1 plan | 2,495 | $9.5K |
| Dec 9, 2024 | Johnston John Joseph Director | Option exercise 10b5-1 plan | 891 | $2.6K |
| Dec 9, 2024 | Johnston John Joseph Director | Option exercise 10b5-1 plan | 483 | $1.4K |
| Dec 6, 2024 | Johnston John Joseph Director | Sale 10b5-1 plan | 505 | $1.9K |
| Dec 6, 2024 | Johnston John Joseph Director | Option exercise 10b5-1 plan | 505 | $1.5K |
| Nov 1, 2024 | Erck Stanley C Director | Option exercise 10b5-1 plan | 47,689 | $1.9K |
| Nov 1, 2024 | Erck Stanley C Director | Sale 10b5-1 plan | 47,689 | $177.4K |
| Oct 28, 2024 | Johnston John Joseph Director | Option exercise 10b5-1 plan | 3,000 | $8.8K |
| Oct 28, 2024 | Johnston John Joseph Director | Sale 10b5-1 plan | 3,000 | $11.2K |
| Oct 14, 2024 | Collins Cynthia Director | Award | 51,679 | $0 |
| Oct 2, 2024 | Erck Stanley C Director | Option exercise 10b5-1 plan | 21,607 | $864 |
| Oct 2, 2024 | Erck Stanley C Director | Sale 10b5-1 plan | 21,607 | $80.2K |
| Oct 1, 2024 | Erck Stanley C Director | Option exercise 10b5-1 plan | 26,082 | $1.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MAXCYTE, INC.
Free account. Everything above stays public.
Write why you follow MAXCYTE, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading